Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for
several years, by non-motor symptoms that include hyposmia, sleep disorders, depression …

With the growing awareness of the presence of non-motor symptoms in Parkinson's disease
(PD) has come the realization that these non-motor features play a tremendously important …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Nonmotor symptoms (NMS) are common in patients with established Parkinson's disease
(PD) and have a major impact upon quality of life. We investigated the significance of NMS …

The first years of Parkinson disease (PD) treatment are marked by good and sustained
responses to dopaminergic therapy. With disease progression and longer exposure to …

Deep brain stimulation of the subthalamic nucleus is an effective and established therapy for
patients with advanced Parkinson's disease improving quality of life, motor symptoms and …

Objective Real‐life observational report of clinical efficacy of bilateral subthalamic
stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on …

We analyzed features associated with a reduction in Health-Related Quality of Life (HRQoL)
in people with idiopathic Parkinson's disease (PD). As a new approach, features were …

Non-motor symptoms are a key component of Parkinson's disease, possibly representing a
clinical biomarker of its premotor phase. The burden of non-motor symptoms can define a …

The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's
disease (PD) for over 40 years. However, the response to this treatment changes with …